Osteoporos Int 22:391–420PubMedCrossRef 75. Copanlisib Kanis JA, Johnell O, Oden A, EPZ5676 purchase Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRef 76. WHO (2007) Assessment of osteoporosis at the primary health care level. WHO, Geneva. At: www.​who.​int/​chp/​topics/​rheumatic/​en/​index.​html. Accessed May 2012 77. Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance

of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef 78. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244PubMedCrossRef 79. Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRef

80. Hans DB, Kanis JA, Baim S et al (2011) Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom 14:171–180PubMedCrossRef 81. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef 82. Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162PubMedCrossRef Selleck BIBW2992 83. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816PubMedCrossRef 84. Papaioannou A, Morin S, Cheung AM et al (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873PubMedCrossRef 85. Orimo H, Nakamura T, Fukunaga M (2006) Japanese guidelines Thymidine kinase for the prevention and treatment of osteoporosis (Translated Abridged Edition) 86. Baim S, Binkley N, Bilezikian JP,

Kendler DL, Hans DB, Lewiecki EM, Silverman S (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 11:75–91PubMedCrossRef 87. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847PubMedCrossRef 88. Leslie WD, Kovacs CS, Olszynski WP, Towheed T, Kaiser SM, Prior JC, Josse RG, Jamal SA, Kreiger N, Goltzman D (2011) Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX®: a population-based report from CAMOS. J Clin Densitom 14:286–293PubMedCrossRef 89.